17-44385705-GGGGGCGCAGGCCT-G
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2_SupportingPS3PP4_StrongPM3PVS1_Strong
This summary comes from the ClinGen Evidence Repository: The c.409-2_419del variant was first reported in the Palestinian population by PMID:2014236; haplotype analysis in PMID:16359514 is consistent with a founder effect. This variant has also been described as c.409-3_418del and HGVS nomenclature is c.409-4_417del. The deletion causes use of a cryptic splice site at position c.425_426 (confirmed in patient mRNA in PMID:2014236). As such there is an in-frame deletion of 18bp encompassing 6 amino acids (Ala137 through Gln142) in the critical ligand binding beta-propeller domain. This variant is absent from all population databases, including gnomAD. The variant has been identified homozygous in at least 8 patients (PMIDs: 2014236, 16359514). with a phenotype highly specific to GT. Transfection in BHK cells resulted in lack of surface expression of αIIbβ3 (PMID:16359514). In summary this variant is classified as Pathogenic for GT. GT-specific criteria applied: PVS1_strong, PS3, PM2_supporting, PM3, PP4_strong. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10575471/MONDO:0010119/011
Frequency
Consequence
NM_000419.5 splice_acceptor, coding_sequence
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ITGA2B | NM_000419.5 | c.409-2_419del | splice_acceptor_variant, coding_sequence_variant | 4/30 | ENST00000262407.6 | NP_000410.2 | ||
ITGA2B | XM_011524749.2 | c.562-2_572del | splice_acceptor_variant, coding_sequence_variant | 4/29 | XP_011523051.2 | |||
ITGA2B | XM_011524750.2 | c.562-2_572del | splice_acceptor_variant, coding_sequence_variant | 4/29 | XP_011523052.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ITGA2B | ENST00000262407.6 | c.409-2_419del | splice_acceptor_variant, coding_sequence_variant | 4/30 | 1 | NM_000419.5 | ENSP00000262407 | P1 | ||
ITGA2B | ENST00000592944.1 | n.92_104del | non_coding_transcript_exon_variant | 1/6 | 5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Glanzmann thrombasthenia Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen | May 07, 2021 | The c.409-2_419del variant was first reported in the Palestinian population by PMID: 2014236; haplotype analysis in PMID: 16359514 is consistent with a founder effect. This variant has also been described as c.409-3_418del and HGVS nomenclature is c.409-4_417del. The deletion causes use of a cryptic splice site at position c.425_426 (confirmed in patient mRNA in PMID: 2014236). As such there is an in-frame deletion of 18bp encompassing 6 amino acids (Ala137 through Gln142) in the critical ligand binding beta-propeller domain. This variant is absent from all population databases, including gnomAD. The variant has been identified homozygous in at least 8 patients (PMIDs: 2014236, 16359514). with a phenotype highly specific to GT. Transfection in BHK cells resulted in lack of surface expression of αIIbβ3 (PMID: 16359514). In summary this variant is classified as Pathogenic for GT. GT-specific criteria applied: PVS1_strong, PS3, PM2_supporting, PM3, PP4_strong. - |
Glanzmann thrombasthenia 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 12, 1991 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at